中文
English
한국어
日本語
Español
Français
Русский
| カタログ番号 | YP598016 | ||||
|---|---|---|---|---|---|
| 説明 |
Idarucizumab (YP598016) is a research-grade recombinant antibody targeting Dabigatran Etexilate Mesylate. Produced in mammalian cells with native-like glycosylation.
Highlights
|
||||
| 種反応性 | General | ||||
| アプリケーション | ELISA, Bioactivity: FACS, Functional assay, Research in vivo | ||||
| 宿主種 | Human | ||||
| クローン性 | Monoclonal | ||||
| アイソタイプ | Fab-G1-kappa | ||||
| 発現システム | Mammalian cells | ||||
| ターゲット | Dabigatran Etexilate Mesylate | ||||
| エンドトキシンレベル | < 10 EU/mg | ||||
| 純度 | >95% purity as determined by SDS-PAGE. | ||||
| 精製 | Protein A/G purified from cell culture supernatant. | ||||
| アクセッション番号 | CAS: 211915-06-9 | ||||
| 形態 | Liquid | ||||
| 保存バッファー | 0.01M PBS pH 7.4 データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
||||
| 製品使用情報 |
| ||||
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. | ||||
| 別名 | aDabi-Fab, anti-dabigatran, antidotefordabigatran, CAS: 1362509-93-0 | ||||
| 背景 | Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis. • Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial., PMID:33290737 • Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism., PMID:35699915 • The polymorph landscape of dabigatran etexilate mesylate: Taking the challenge to bring a metastable polymorph to market., PMID:37044200 • Dose tailoring of dabigatran etexilate: obvious or excessive?, PMID:25994994 • A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects., PMID:31652461 • Idarucizumab for Dabigatran Reversal - Full Cohort Analysis., PMID:28693366 • Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation., PMID:28185082 • Direct oral anticoagulants: evidence and unresolved issues., PMID:33248499 • Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta., PMID:24807346 • The discovery of dabigatran etexilate for the treatment of venous thrombosis., PMID:27159158 | ||||
| 注意事項 | For research use only. Not suitable for clinical or therapeutic use. | ||||
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
SDS-PAGE for Research Grade Idarucizumab
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206
